IOTA Pharmaceuticals


IOTA Pharmaceuticals

Fragment - based Drug Discovery
Neglected Parasitic Disease
Glioma & Glioblastoma
About IOTA Pharmaceuticals

IOTA's Medicinal Chemistry is focused on translating fragment based chemical designs into optimised lead molecules for both IOTA's own drug discovery and our client-driven programmes. IOTA's integrated Drug Discovery Partnerships range from target-based hit discovery programmes to cell-based phenotypic screening campaigns.

IOTA's hit-to-lead efforts are headed by Dr Fredrik Svensson, and include structure-based design, exploratory medicinal chemistry and screening, as well as ADME-T optimization of resulting hits.

Further information about partnering with IOTA in specific Drug Discovery Partnerships can be obtained by contacting us on